AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discussion on Eli Lilly's Acquisition of Morphic and Drug Pricing in the Pharmaceutical Industry
This chapter delves into Eli Lilly's $3.2 billion acquisition of Morphic, M&A trends in healthcare, discussions on drug pricing, middlemen in the pharmaceutical industry, and the importance of competition to reduce prices. The chapter also introduces Sam Fazelli, a healthcare pharma analyst, and mentions Think or Swim trading platform and CrowdStrike cybersecurity platform.